Evidence map›Paper›PMID 40055861›Full record

Observational studyJournal of the American Heart Association2025

Signal-Averaged ECG in the Diagnostic Workup for Arrhythmogenic Cardiomyopathy: Insights From the Nordic ARVC Registry.

Aleksei A Savelev, Eivind W Aabel, Anneli Svensson, Pia Dahlberg, Alex Hørby Christensen, Trine Madsen, Henning Bundgaard, Tiina Heliö, Aevar Ulfarsson, Thor Edvardsen and 4 more

Abstract readObservational Study
In one paragraph

Observational study in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Aleksei A SavelevDepartment of Cardiology, Clinical Sciences Lund University Lund Sweden.ORCID 0000-0002-5198-7525
Eivind W AabelProCardio Center for Innovation, Department of Cardiology Oslo University Hospital Oslo Norway.ORCID 0000-0002-2022-4568
Anneli SvenssonDepartment of Cardiology and Department of Health, Medicine and Caring Sciences Linköping University Linköping Sweden.ORCID 0000-0001-8404-0541
Pia DahlbergDepartment of Cardiology, Department of Molecular and Clinical Medicine Institute of Medicine, Sahlgrenska University Hospital Gothenburg Sweden.ORCID 0000-0003-3344-1796
Alex Hørby ChristensenDepartment of Cardiology Copenhagen University Hospital - Herlev-Gentofte Copenhagen Denmark.ORCID 0000-0002-6855-1496
Trine MadsenDepartment of Cardiology Aalborg University Hospital Aalborg Denmark.
Henning BundgaardDepartment of Cardiology Copenhagen University Hospital - Rigshospitalet Copenhagen Denmark.ORCID 0000-0002-0563-7049
Tiina HeliöHeart and Lung Center Helsinki University Hospital and University of Helsinki Helsinki Finland.ORCID 0000-0002-9640-9040
Aevar UlfarssonDepartment of Cardiology, Clinical Sciences Lund University Lund Sweden.ORCID 0000-0001-8461-4496
Thor EdvardsenProCardio Center for Innovation, Department of Cardiology Oslo University Hospital Oslo Norway.ORCID 0000-0002-3800-765X
Jesper H SvendsenDepartment of Cardiology Copenhagen University Hospital - Rigshospitalet Copenhagen Denmark.ORCID 0000-0001-8466-8515
Henrik K JensenDepartment of Cardiology Aarhus University Hospital Aarhus Denmark.ORCID 0000-0003-1802-4302
Kristina H HaugaaProCardio Center for Innovation, Department of Cardiology Oslo University Hospital Oslo Norway.ORCID 0000-0002-4900-0453
Pyotr G PlatonovDepartment of Cardiology, Clinical Sciences Lund University Lund Sweden.ORCID 0000-0002-5592-8717

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe diagnostic role of signal-averaged ECG (SAECG) in arrhythmogenic right ventricular cardiomyopathy (ARVC) has lately been questioned. We assessed the value of SAECG-derived late ventricular potentials (LP) in ARVC diagnosis and its association with disease manifestations. METHODS AND

resultsPatients with definite ARVC diagnosis or genotype-positive family members who underwent SAECG were included in register-based observational study (n=357, mean age 41 years, 47% female, 43% probands). LP and terminal activation duration (TAD) were defined by Task Force Criteria 2010. We assessed the association of TAD and LP with structural RV abnormalities and ventricular tachycardia (VT), defined as sustained VT, appropriate implantable cardioverter-defibrillator shock, aborted cardiac arrest, or sudden cardiac death, at diagnosis. LP were documented in 210 patients (59%) and abnormal TAD in 66 patients (18%). Each of the SAECG parameters was significantly associated with definite ARVC diagnosis in receiver-operator characteristics curve analysis with area under the curve between 0.67 and 0.74. Exclusion of SAECG from diagnostic workup led to reclassification of 37 patients (16%) from definite to borderline ARVC (13 probands, 9 of whom had prevalent VT). Ninety patients (25%) had history of VT. LP, but not TAD, were associated with VT (adjusted odds ratio [OR

conclusionsIn the Nordic ARVC cohort SAECG-derived LP are associated with VT and structural RV abnormalities and were critical for ascertainment of ARVC diagnosis in 16% of patients with narrow QRS complexes, including 8% of all probands.

Indexed as

Arrhythmogenic Right Ventricular DysplasiaElectrocardiographyAction PotentialsAdultDeath, Sudden, CardiacFemaleHeart RateHumansMaleMiddle AgedPredictive Value of TestsRegistriesROC CurveScandinavian and Nordic CountriesTachycardia, Ventriculararrhythmogenic cardiomyopathyarrhythmogenic right ventricular cardiomyopathyARVCsignal‐averaged ECGventricular late potentials

Identifiers

PMID40055861
PMCPMC12132728

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.